<DOC>
	<DOCNO>NCT01691898</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate safety efficacy pinatuzumab vedotin ( DCDT2980S ) polatuzumab vedotin ( DCDS4501A ) combination rituximab ( RTX ) , well combination polatuzumab vedotin obinutuzumab participant relapse refractory follicular non-Hodgkin 's lymphoma ( NHL ) relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>A Study Pinatuzumab Vedotin ( DCDT2980S ) Combined With Rituximab Polatuzumab Vedotin ( DCDS4501A ) Combined With Rituximab Obinutuzumab Participants With Relapsed Refractory B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Life expectancy least 12 week History histologically document relapsed refractory Grades 1 3a follicular lymphoma ( FL ) , relapse refractory DLBCL Availability archival freshly biopsied tumor tissue sample must confirm study enrollment Have clinical indication treatment determine investigator Must least one bidimensionally measurable lesion ( great [ &gt; ] 1.5 centimeter [ cm ] large dimension CT scan magnetic resonance image [ MRI ] ) Prior use monoclonal antibody , radioimmunoconjugate antibody drug conjugate within 4 week study start Treatment radiotherapy , chemotherapy , immunotherapy , immunosuppressive therapy , investigational anticancer agent within 2 week prior study start Adverse event except sensory neuropathy previous treatment must resolve stabilized grade less equal ( &lt; = ) 2 prior study start Completion autologous stem cell transplant ( SCT ) within 100 day prior study start Prior allogeneic SCT Eligibility autologous SCT ( participant relapse refractory DLBCL ) History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) History malignancy could affect compliance protocol interpretation result Current past history central nervous system lymphoma Current Grade &gt; 1 peripheral neuropathy Vaccination live vaccine within 28 day prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>